Peroxisome proliferator-activated receptors (PPARs) have multiple binding points that accommodate ligands in various conformations: phenylpropanoic acid-type PPAR ligands bind to PPAR in different conformations, depending on the subtype.

Human peroxisome proliferator-activated receptors (hPPARs) are ligand-dependent transcription factors that control various biological responses, and there are three subtypes: hPPARα, hPPARδ, and hPPARγ. We report here that α-substituted phenylpropanoic acid-type hPPAR agonists with similar structure bind to the hPPAR ligand binding domain (LBD) in different conformations, depending on the receptor subtype. These results might indicate that hPPAR ligand binding pockets have multiple binding points that can be utilized to accommodate structurally flexible hPPAR ligands.

[1]  G. Landreth.  Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer's disease. , 2007, Current Alzheimer research.

[2]  R. Evans,et al.  Nuclear receptors and lipid physiology: opening the X-files. , 2001, Science.

[3]  Shuichi Hirono,et al.  Design, synthesis, and structural analysis of phenylpropanoic acid-type PPARγ-selective agonists: discovery of reversed stereochemistry-activity relationship. , 2011, Journal of medicinal chemistry.

[4]  V. N. Molchanov,et al.  Superconducting Single Crystals of Tl2Ba2CaCu2O8 and YBa2Cu4O8: Crystal Structures in the Vicinity of Tc , 1998 .

[5]  Dasheng Wang,et al.  Development of small-molecule cyclin D1-ablative agents. , 2006, Journal of medicinal chemistry.

[6]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[7]  J. Fetrow.  Omega loops; nonregular secondary structures significant in protein function and stability , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  M. Makishima,et al.  SAR-oriented discovery of peroxisome proliferator-activated receptor pan agonist with a 4-adamantylphenyl group as a hydrophobic tail. , 2008, Bioorganic & medicinal chemistry letters.

[9]  M. Makishima,et al.  Design, synthesis, and evaluation of potent, structurally novel peroxisome proliferator-activated receptor (PPAR) δ-selective agonists , 2007 .

[10]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. , 1996, Annual review of cell and developmental biology.

[11]  Igor Polikarpov,et al.  Ajulemic Acid, a Synthetic Nonpsychoactive Cannabinoid Acid, Bound to the Ligand Binding Domain of the Human Peroxisome Proliferator-activated Receptor γ* , 2007, Journal of Biological Chemistry.

[12]  Nanping Wang,et al.  Role of peroxisome proliferator-activated receptor-γ in atherosclerosis: an update. , 2011, Circulation journal : official journal of the Japanese Circulation Society.

[13]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[14]  S. Hirono,et al.  Structure-based design, synthesis, and nonalcoholic steatohepatitis (NASH)-preventive effect of phenylpropanoic acid peroxisome proliferator-activated receptor (PPAR) α-selective agonists. , 2011, Bioorganic & medicinal chemistry.

[15]  M. Makishima,et al.  Design, synthesis, and evaluation of a novel series of alpha-substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor (PPAR) alpha/delta dual agonists for the treatment of metabolic syndrome. , 2006, Bioorganic & medicinal chemistry.

[16]  L. Moore,et al.  Subtype specific effects of peroxisome proliferator-activated receptor ligands on corepressor affinity. , 2003, Biochemistry.

[17]  Millard H. Lambert,et al.  Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARα , 2002, Nature.

[18]  R. Kaundal,et al.  Peroxisome proliferator-activated receptor gamma agonists as neuroprotective agents. , 2010, Drug news & perspectives.

[19]  Gerard J. Kleywegt,et al.  Crystallographic refinement of ligand complexes , 2006, Acta crystallographica. Section D, Biological crystallography.

[20]  Nanping Wang,et al.  Role of peroxisome proliferator-activated receptor-γ in atherosclerosis: an update. , 2011, Circulation journal : official journal of the Japanese Circulation Society.

[21]  J. Lehmann,et al.  Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. , 2000, Molecular cell.

[22]  G. Landreth.  Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer's disease. , 2007, Current Alzheimer research.

[23]  L. Jendeberg,et al.  A New Class of Peroxisome Proliferator-activated Receptor Agonists with a Novel Binding Epitope Shows Antidiabetic Effects* , 2004, Journal of Biological Chemistry.

[24]  J. Auwerx,et al.  Peroxisome proliferator-activated receptors, orphans with ligands and functions. , 1997, Current opinion in lipidology.

[25]  M. Mendez,et al.  PPAR&ggr; Inhibition of Cyclooxygenase-2, PGE2 Synthase, and Inducible Nitric Oxide Synthase in Cardiac Myocytes , 2003, Hypertension.

[26]  M. Makishima,et al.  Improvement of the transactivation activity of phenylpropanoic acid-type peroxisome proliferator-activated receptor pan agonists: effect of introduction of fluorine at the linker part. , 2008, Bioorganic & medicinal chemistry letters.

[27]  N. Blomberg,et al.  Structure of the PPARα and -γ Ligand Binding Domain in Complex with AZ 242; Ligand Selectivity and Agonist Activation in the PPAR Family , 2001 .

[28]  N. Blomberg,et al.  Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family. , 2001, Structure.

[29]  M. Makishima,et al.  Determination of the Critical Amino Acids Involved in the Peroxisome Proliferator‐Activated Receptor (PPAR) δ Selectivity of Phenylpropanoic Acid‐Derived Agonists , 2008, ChemMedChem.

[30]  R. Morrison,et al.  Role of PPARγ in Regulating a Cascade Expression of Cyclin-dependent Kinase Inhibitors, p18(INK4c) and p21(Waf1/Cip1), during Adipogenesis* , 1999, The Journal of Biological Chemistry.

[31]  Y. Hashimoto,et al.  Adaptability and selectivity of human peroxisome proliferator-activated receptor (PPAR) pan agonists revealed from crystal structures , 2009, Acta crystallographica. Section D, Biological crystallography.

[32]  J. Gustafsson,et al.  A systematic analytical chemistry/cell assay approach to isolate activators of orphan nuclear receptors from biological extracts: characterization of peroxisome proliferator-activated receptor activators in plasma. , 1993, Journal of lipid research.